Literature DB >> 26360252

Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C.

Diane M Da Silva1, Andrew W Woodham2, Joseph G Skeate3, Laurie K Rijkee4, Julia R Taylor2, Heike E Brand2, Laila I Muderspach5, Lynda D Roman5, Annie A Yessaian5, Huyen Q Pham5, Koji Matsuo5, Yvonne G Lin5, Greg M McKee6, Andres M Salazar7, W Martin Kast8.   

Abstract

Human papillomavirus (HPV)-mediated suppression of Langerhans cell (LC) function can lead to persistent infection and development of cervical intraepithelial neoplasia (CIN). Women with HPV-induced high-grade CIN2/3 have not mounted an effective immune response against HPV, yet it is unknown if LC-mediated T cell activation from such women is functionally impaired against HPV. We investigated the functional activation of in vitro generated LC and their ability to induce HPV16-specific T cells from CIN2/3 patients after exposure to HPV16 followed by treatment with stabilized Poly-I:C (s-Poly-I:C). LC from patients exposed to HPV16 demonstrated a lack of costimulatory molecule expression, inflammatory cytokine secretion, and chemokine-directed migration. Conversely, s-Poly-I:C caused significant phenotypic and functional activation of HPV16-exposed LC, which resulted in de novo generation of HPV16-specific CD8(+) T cells. Our results highlight that LC of women with a history of persistent HPV infection can present HPV antigens and are capable of inducing an adaptive T cell immune response when given the proper stimulus, suggesting that s-Poly-I:C compounds may be attractive immunomodulators for LC-mediated clearance of persistent HPV infection.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HPV16; Human papillomavirus; Immune evasion; Langerhans cells

Mesh:

Substances:

Year:  2015        PMID: 26360252      PMCID: PMC4658296          DOI: 10.1016/j.clim.2015.09.003

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  76 in total

1.  TLR activation of Langerhans cell-like dendritic cells triggers an antiviral immune response.

Authors:  Claudia N Renn; David Jesse Sanchez; Maria Teresa Ochoa; Annaliza J Legaspi; Chang-Keun Oh; Philip T Liu; Stephan R Krutzik; Peter A Sieling; Genhong Cheng; Robert L Modlin
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

Review 2.  Toll-like receptor and RIG-I-like receptor signaling.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

3.  Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.

Authors:  H L Greenstone; J D Nieland; K E de Visser; M L De Bruijn; R Kirnbauer; R B Roden; D R Lowy; W M Kast; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

4.  Papillomavirus-like particles induce acute activation of dendritic cells.

Authors:  P Lenz; P M Day; Y Y Pang; S A Frye; P N Jensen; D R Lowy; J T Schiller
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

5.  Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy.

Authors:  Robert M Prins; Horacio Soto; Vera Konkankit; Sylvia K Odesa; Ascia Eskin; William H Yong; Stanley F Nelson; Linda M Liau
Journal:  Clin Cancer Res       Date:  2010-12-06       Impact factor: 12.531

6.  Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens.

Authors:  M Nakagawa; D P Stites; S Patel; S Farhat; M Scott; N K Hills; J M Palefsky; A B Moscicki
Journal:  J Infect Dis       Date:  2000-07-28       Impact factor: 5.226

7.  Integration of high-risk human papillomavirus DNA correlates with HLA genotype aberration and reduced HLA class I molecule expression in human cervical carcinoma.

Authors:  Bor-Ching Sheu; Shin-Heng Chiou; Wen-Chun Chang; Song-Nan Chow; Ho-Hsiung Lin; Ruey-Jien Chen; Su-Cheng Huang; Hong-Nerng Ho; Su-Ming Hsu
Journal:  Clin Immunol       Date:  2005-06       Impact factor: 3.969

8.  Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells.

Authors:  Eynav Klechevsky; Rimpei Morita; Maochang Liu; Yanying Cao; Sebastien Coquery; Luann Thompson-Snipes; Francine Briere; Damien Chaussabel; Gerard Zurawski; A Karolina Palucka; Yoram Reiter; Jacques Banchereau; Hideki Ueno
Journal:  Immunity       Date:  2008-09-19       Impact factor: 31.745

9.  Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections.

Authors:  Ana Cecilia Rodríguez; Mark Schiffman; Rolando Herrero; Sholom Wacholder; Allan Hildesheim; Philip E Castle; Diane Solomon; Robert Burk
Journal:  J Natl Cancer Inst       Date:  2008-03-25       Impact factor: 13.506

10.  Cross-platform comparison of SYBR Green real-time PCR with TaqMan PCR, microarrays and other gene expression measurement technologies evaluated in the MicroArray Quality Control (MAQC) study.

Authors:  Emi Arikawa; Yanyang Sun; Jie Wang; Qiong Zhou; Baitang Ning; Stacey L Dial; Lei Guo; Jingping Yang
Journal:  BMC Genomics       Date:  2008-07-11       Impact factor: 3.969

View more
  8 in total

Review 1.  Evasion of host immune defenses by human papillomavirus.

Authors:  Joseph A Westrich; Cody J Warren; Dohun Pyeon
Journal:  Virus Res       Date:  2016-11-24       Impact factor: 3.303

Review 2.  Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.

Authors:  Joseph G Skeate; Andrew W Woodham; Mark H Einstein; Diane M Da Silva; W Martin Kast
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

Review 3.  Modulation of antigen presenting cell functions during chronic HPV infection.

Authors:  Abate Assefa Bashaw; Graham R Leggatt; Janin Chandra; Zewen K Tuong; Ian H Frazer
Journal:  Papillomavirus Res       Date:  2017-08-18

4.  Circulating immune parameters-based nomogram for predicting malignancy in laryngeal neoplasm.

Authors:  Min Chen; Yi Fang; Yue Yang; Pei-Jie He; Lei Cheng; Hai-Tao Wu
Journal:  World J Clin Cases       Date:  2021-01-26       Impact factor: 1.337

5.  Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells.

Authors:  Diane M Da Silva; Andrew W Woodham; Paul H Naylor; James E Egan; Neil L Berinstein; W Martin Kast
Journal:  J Interferon Cytokine Res       Date:  2015-12-10       Impact factor: 2.607

6.  T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation.

Authors:  Andrew W Woodham; Lisa Yan; Joseph G Skeate; Daniel van der Veen; Heike H Brand; Michael K Wong; Diane M Da Silva; W Martin Kast
Journal:  Papillomavirus Res       Date:  2016-12

Review 7.  Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.

Authors:  Ruan F V Medrano; Aline Hunger; Samir Andrade Mendonça; José Alexandre M Barbuto; Bryan E Strauss
Journal:  Oncotarget       Date:  2017-07-25

Review 8.  A review of the research progress in T-lymphocyte immunity and cervical cancer.

Authors:  Lina Zhang; Zhilei Mao; Yiqing Lai; Ting Wan; Keliang Zhang; Beibei Zhou
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.